Inclusion Criteria:

• * For Parts A, B, C, E, Overtly healthy males or females as determined by medical history and physical examination.
• * For Parts A, B, C, E, have a screening body mass index (BMI) in the range of 18.5 to 35 kg/m2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening.
• * For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China
• * For Part Part D, participants with obesity and hypertension must have a stable dose of antihypertensive medications within the past 3 months prior to screening.
• * For Part D, obesity BMI in the range of 30 to 40 kg/m2, inclusive, with a waist circumference of at least 102 cm for men and at least 89 cm for women.
• * For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.
• * Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential.

Exclusion Criteria:

• * Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
• * Have known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation
• * Have blood pressure and/or pulse rate constituting a risk as determined by the investigator.
• * Have a systolic BP of less than 100 mmHg.
• * Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position.
• * For US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study.
• * For Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening
• * Consume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine.
• * Have alcohol intake that exceeds recommended alcohol consumption limits per local regulation, or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge.
• * For Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat).
• * For Part D, has concurrent or anticipated use of long-acting nitrates or NO donors.
• * For Part D, has concurrent or anticipated use of beta blockers.
• * For Part D, has current use of more than 3 mechanism of actions for treatment of hypertension.